Health Affairs January 27, 2023
The Inflation Reduction Act (IRA) mandated the creation of a Drug Price Negotiation Program (DPNP) focused on developing a process for Medicare to engage manufacturers in efforts to reduce the prices of certain products paid for under Medicare Part B and Part D. While there are several limitations to which drugs may be selected and what criteria the Centers for Medicare and Medicaid Services (CMS) can use within the new DPNP, interpretation and implementation of this legislation creates new opportunities for engaging patients and caregivers in a meaningful way.
The IRA explicitly identifies nine factors that Medicare may consider “as applicable to the drug, as the basis for determining the offers and counteroffers” when negotiating the maximum fair price. At...
Today's Sponsors
Today's Sponsor